Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467779 · ClinicalTrials.gov registry record · Phase 1
Study of Cobimetinib in Participants With Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT00467779 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 119 participants.
The verdict
NCT00467779, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
This non-randomized, open-label, study will determine the highest safe dose of cobimetinib, how often it should be taken, how well participants with cancer tolerate cobimetinib and will assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.
Interventions
- DRUG midazolam
- DRUG dextromethorphan
- DRUG cobimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2007-05 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00467779
The ClinicalTrials.gov registry entry for NCT00467779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which midazolam is the first listed.
NCT00467779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00467779 about?
NCT00467779 is a clinical study titled "Study of Cobimetinib in Participants With Solid Tumors". This non-randomized, open-label, study will determine the highest safe dose of cobimetinib, how often it should be taken, how well participants with cancer tolerate cobimetinib and will assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.
What is the current status of trial NCT00467779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2007-05. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00467779?
The interventions under investigation include: midazolam (DRUG), dextromethorphan (DRUG), cobimetinib (DRUG).
Who is sponsoring clinical trial NCT00467779?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.